ADOC regimen
WikiDoc Resources for ADOC regimen |
Articles |
---|
Most recent articles on ADOC regimen Most cited articles on ADOC regimen |
Media |
Powerpoint slides on ADOC regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on ADOC regimen at Clinical Trials.gov Clinical Trials on ADOC regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on ADOC regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on ADOC regimen Discussion groups on ADOC regimen Patient Handouts on ADOC regimen Directions to Hospitals Treating ADOC regimen Risk calculators and risk factors for ADOC regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for ADOC regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
ADOC regimen refers to an immunochemotherapy regimen consisting of doxorubicin (Adriamycin), cisplatin (cis-Diamminedichloroplatinum), vincristine (Oncovin), cyclophosphamide used to treat invasive thymoma.[1]
Regimen
D – Cisplatin (Cis-Diamminedichloroplatinum)
Indications
References
- ↑ 1.0 1.1 Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F; et al. (1991). "Chemotherapy for invasive thymoma. A 13-year experience". Cancer. 68 (1): 30–3. PMID 2049749.